entireti
ubiquitin
proteasom
system
up
involv
intric
network
hundr
enzym
regul
major
mechan
degrad
damag
unrequir
protein
eukaryot
cell
simplist
process
wherebi
protein
tag
shred
proteasom
larg
multisubunit
complex
consist
proteolyt
core
one
two
regulatori
particl
tag
use
process
ubiquitin
amino
acid
approxim
kda
peptid
ubiquitin
tag
attach
monom
polyubiquitin
chain
attach
isopeptid
bond
form
carboxytermin
glycin
ubiquitin
group
lysin
residu
substrat
protein
ubiquitin
contain
seven
expos
lysin
residu
addit
nterminu
provid
eight
link
option
situat
form
part
polyubiquitin
chain
exact
connect
linkag
provid
detail
messag
tag
polyubiquitin
chain
commonli
use
flag
protein
substrat
proteasom
degrad
unwant
protein
ubiquitin
via
sequenti
action
ubiquitinactiv
enzym
ubiquitinconjug
enzym
ubiquitin
ligas
man
high
substrat
specif
achiev
select
utilis
one
ligas
final
ubiquitin
transfer
step
tag
process
kept
balanc
class
proteas
remov
ubiquitin
protein
deubiquitin
enzym
dub
dubmedi
remov
ubiquitin
save
tag
protein
degrad
dub
also
involv
subtl
edit
polyubiquitin
signal
necessari
cleav
ubiquitin
precursor
recycl
ubiquitin
monom
despit
field
research
year
full
complex
up
continu
emerg
central
role
regul
homeostasi
involv
mani
aspect
cellular
prolifer
surviv
find
compound
modul
up
therefor
becom
activ
area
research
pharmaceut
compani
becam
valid
therapeut
pathway
approv
proteasom
inhibitor
bortezomib
carfilzomib
respect
treatment
haematolog
malign
figur
compound
preferenti
inhibit
chymotrypsinlik
proteolyt
site
core
sinc
approv
bortezomib
much
effort
target
protein
ubiquitin
deubiquitin
process
upstream
proteasom
search
new
cancer
treatment
clinic
advanc
compound
emerg
far
inhibitor
enzym
subunit
ubiquitinlik
protein
current
phase
clinic
trial
treat
haematolog
malign
solid
tumour
addit
cancer
util
dub
inhibitor
research
across
therapeut
area
includ
neurodegener
haematolog
infecti
diseas
sir
philip
cohen
contrast
research
activ
field
protein
phosphoryl
protein
ubiquitin
theme
perspect
predict
whether
happen
within
kinas
famili
up
would
ever
becom
major
sourc
drug
target
help
inform
evolv
stori
chapter
review
repres
smallmolecul
inhibitor
rang
dub
cover
last
decad
focu
human
dub
although
viral
dub
also
discuss
order
illustr
specif
point
gener
trend
emerg
analysi
discuss
section
note
dub
inhibitor
patent
landscap
also
subject
recent
review
approxim
dub
encod
human
genom
major
cystein
proteas
remaind
zinc
metalloproteas
cystein
proteas
dub
subdivid
four
famili
ubiquitin
ctermin
hydrolas
uch
ubiquitinspecif
proteas
usp
machadojoseph
diseas
proteas
mjd
josephin
ovarian
tumour
proteas
otu
zinc
metalloproteas
dub
known
jamm
famili
also
shown
phylogenet
tree
figur
sentrinsumospecif
proteas
senp
isopeptidas
close
relat
dub
remov
small
ubiquitinlik
modifi
protein
sumo
approxim
kda
peptid
tag
similar
ubiquitin
occur
four
isoform
mammal
analog
manner
ubiquitin
enzym
dub
sumo
enzym
senp
preserv
balanc
sumoyl
unsumoyl
protein
cell
sever
studi
implic
senp
develop
variou
diseas
especi
prostat
cancer
diseas
associ
senp
inhibitor
develop
recent
review
dub
isopeptidas
capabl
bind
ubiquitin
substrat
polyubiquitin
chain
hydrolys
amid
bond
ubiquitin
commonli
lysin
side
chain
ntermin
methionin
case
linear
polyubiquitin
chain
figur
show
reaction
mechan
hydrolysi
zinc
metalloproteas
cystein
proteas
dub
respect
last
two
ctermin
residu
ubiquitin
lack
side
chain
result
narrow
linker
side
isopeptid
bond
consequ
dub
characteris
long
narrow
activ
site
ub
bind
although
structur
dubsubstr
complex
studi
without
mutat
catalyt
residu
addit
apo
dub
xray
structur
sever
xray
structur
dub
complex
warhead
ubiquitin
ie
modifi
ubiquitin
carboxi
group
replac
electrophil
moieti
aldehyd
vinyl
methyl
ester
vme
figur
show
xray
structur
kda
catalyt
domain
cd
also
known
herp
virusassoci
ubiquitinspecif
proteas
hausp
complex
ubiquitin
aldehyd
structur
highlight
characterist
three
subdomain
usp
cd
liken
figur
isopeptid
hydrolysi
reaction
mechan
mediat
cystein
proteas
dub
ub
hu
et
al
finger
palm
thumb
right
hand
cterminu
ubiquitin
aldehyd
orang
grey
print
version
extend
narrow
activ
site
cleft
cd
cyan
grey
print
version
notabl
hu
et
al
also
solv
apo
structur
cd
pdb
found
ubiquitin
bind
induc
drastic
conform
chang
activ
site
realign
activ
catalyt
triad
via
movement
switch
loop
absenc
ubiquitin
bind
catalyt
triad
adopt
inact
conform
cystein
far
away
histidin
hydrolysi
mechan
describ
figur
occur
ubiquitinmedi
activ
catalyt
mechan
elucid
sever
dub
especi
clear
case
one
smallest
famili
member
kda
xray
structur
apo
first
solv
da
et
al
activ
site
found
resembl
typic
cystein
proteas
papain
except
away
catalyt
cystein
result
structur
look
incap
catalyt
activ
pdb
paper
team
specul
substrateinduc
rearrang
would
requir
order
activ
proteas
four
year
later
team
solv
xray
structur
bound
ubiquitin
vme
structur
reveal
aminotermin
ubiquitin
push
distal
site
trigger
domino
effect
via
two
phenylalanin
side
chain
result
push
within
therebi
activ
react
vme
warhead
figur
show
result
structur
pdb
orient
figur
ubiquitin
orang
grey
print
version
purpl
dark
grey
print
version
ubiquitin
highlight
import
substratefilt
crossov
loop
characterist
entir
uch
famili
domino
effect
illustr
figur
superimpos
relev
part
yellow
light
grey
print
version
purpl
dark
grey
print
version
structur
presum
push
ubiquitin
green
grey
print
version
caus
side
chain
swivel
approxim
turn
side
chain
complet
cascad
push
basic
imidazol
ring
nearli
closer
ubiquitinmedi
catalyt
triad
rearrang
requir
dub
exampl
xray
structur
apo
reveal
catalyt
triad
organis
activ
state
howev
case
proteas
autoinhibit
loop
adjac
activ
site
fold
cleft
xray
structur
indic
cd
likewis
catalyt
compet
triad
apo
form
time
alloster
regul
via
one
ubiquitinlik
ubl
domain
ubl
domain
common
within
usp
famili
stretch
amino
acid
share
fold
ubiquitin
locat
either
ntermin
within
ctermin
cd
structur
inform
ubl
addit
domain
dub
interact
continu
emerg
demonstr
recent
public
first
characteris
domain
architectur
discoveri
new
bind
site
via
second
five
ubl
presenc
addit
domain
well
cofactor
usp
theori
provid
multipl
alloster
option
dub
inhibit
also
result
dub
famili
member
vari
greatli
domain
architectur
size
rang
amino
acid
cornucopia
elegantli
analys
categoris
komand
et
al
primari
assay
screen
compound
collect
isol
dub
evolv
rapidli
within
past
decad
initi
figur
overlay
xray
structur
apo
yellow
light
grey
print
version
bound
ubiquitin
vme
enzym
purpl
dark
grey
print
version
ubiquitin
vme
green
grey
print
version
commonli
use
substrat
ubiquitin
coupl
via
carboxyterminu
onto
amino
group
fluoresc
tag
ubamc
fluoresc
polaris
detect
could
utilis
test
whether
compound
capabl
block
dubmedi
cleavag
ubamc
amc
although
simpl
rel
old
technolog
prone
pick
fluoresc
artefact
importantli
ubamc
poor
job
mimick
natur
dub
substrat
sinc
flat
bicycl
amc
group
differ
narrow
side
chain
lysin
altern
tag
less
prone
fluoresc
artefact
subsequ
incorpor
rhodaminerho
tetramethylrhodamin
tamra
result
ubrho
ubtamra
substrat
closer
genuin
dub
substrat
ubamc
signific
improv
use
substrat
lysin
residu
link
via
group
insert
ubiquitin
tag
anoth
techniqu
known
ubchop
utilis
report
enzym
pla
conjug
onto
ubiquitin
pla
inact
conjug
form
becom
catalyt
activ
ubpla
bond
hydrolys
activ
free
pla
proce
cleav
fluorescenttag
substrat
complic
isol
cystein
proteas
dub
assay
requir
ad
reduc
agent
dithiothreitol
dtt
prevent
cystein
oxid
keep
enzym
viabl
research
astrazeneca
show
chang
either
concentr
natur
reduc
agent
consider
effect
result
ic
valu
inhibitor
henc
experiment
condit
need
consid
compar
potenc
inhibitor
differ
public
recent
screen
dub
utilis
diubiquitin
substrat
matrixassist
laser
desorpt
ionis
timeofflight
malditof
mass
spectrometri
ms
utilis
detect
techniqu
identifi
inhibitor
advantag
use
unmodifi
substrat
describ
later
wide
dub
profil
techniqu
led
reevalu
select
literatur
dub
inhibitor
activ
probe
assay
also
recent
optimis
dub
measur
inhibitor
abil
prevent
dub
react
irrevers
appropri
warhead
ubiquitin
polyubiquitin
optimis
lowthroughput
western
blot
assay
much
higher
throughput
version
potenti
inhibitor
test
wholecel
tissu
system
follow
lyse
compet
noncellpenetr
activ
probe
physiolog
relev
isol
dub
solut
arbitrari
reduc
agent
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
two
six
known
human
coronavirus
highli
pathogen
potenti
human
human
transmiss
contain
papainlik
cystein
proteas
term
sarscov
plpro
merscov
plpro
respect
addit
process
viral
polyprotein
proteas
function
dub
also
deisgyl
enzym
remov
ubiquitin
anoth
ubiquitinlik
peptid
host
cell
protein
result
antagon
host
antivir
immun
respons
henc
sarscov
plpro
merscov
plpro
propos
import
antivir
target
xray
structur
proteas
solv
found
similar
usp
famili
dub
sarscov
plpro
receiv
attent
sever
group
identifi
inhibitor
chou
et
al
discov
immunosuppress
thiopurin
drug
figur
weak
ligandeffici
inhibitor
sarscov
plpro
group
recent
found
compound
similar
potenc
merscov
plpro
case
group
use
comput
dock
studi
predict
similar
bind
mode
common
caviti
near
catalyt
triad
two
plpro
enzym
mesecar
ghosh
group
identifi
low
inhibitor
sarscov
plpro
highthroughput
screen
approxim
compound
rlrggamc
ctermin
ubamc
substrat
compound
optimis
result
ic
sarscov
plpro
ec
antivir
cellbas
assay
figur
xray
structur
sarscov
plpro
show
bind
within
subsit
proteas
pdb
equat
region
side
chain
ubiquitin
bind
year
team
report
seri
public
compound
relat
seri
retain
naphthyl
group
bind
subsit
sarscov
plpro
pdb
recent
public
show
twofold
potenc
improv
achiev
chang
benzodioxolan
phenyl
give
compound
ic
antivir
ec
xray
structur
purpl
dark
grey
print
version
sarscov
plpro
green
grey
print
version
shown
figur
view
orient
use
subsit
although
site
appreci
differ
usp
consist
select
seri
repres
notabl
bind
site
compound
also
compound
approxim
region
distal
bind
site
complex
figur
also
ligandbind
site
describ
later
although
progress
sarscov
plpro
inhibitor
optimis
slow
nonetheless
encourag
see
inhibitor
rel
potent
devoid
toxicophor
bind
proteas
structur
similar
human
dub
high
lipophil
free
benzyl
posit
compound
surprisingli
unstabl
mous
liver
microsom
min
howev
polar
analogu
demonstr
signific
stabil
improv
made
without
sacrif
much
potenc
sarscov
plpro
bisthiocyan
figur
first
describ
altun
et
al
broad
panel
dub
inhibitor
studi
use
compound
inhibit
wide
rang
dub
cellular
activ
probe
assay
interestingli
although
found
inhibit
dub
famili
sampl
uspuchmjd
well
plpro
core
ic
around
fivefold
weaker
repres
nondub
cystein
proteas
cathepsin
b
mode
inhibit
describ
mission
therapeut
likewis
found
act
good
posit
control
dub
assay
run
inhous
recent
studi
dub
select
literatur
inhibitor
malditof
ms
agre
strongli
inhibit
dub
test
cover
uspuchmjdotu
famili
diterpen
curcuson
describ
broad
inhibitor
usp
signific
effect
cell
reactiv
oxygen
speci
surprisingli
unaffect
becom
anticanc
target
role
regul
dna
damag
respons
pathway
one
dub
requir
interact
partner
protein
full
activ
case
cofactor
factor
highthroughput
screen
nine
half
thousand
bioactiv
compound
complex
use
ubrho
substrat
zhuang
group
identifi
sever
low
hit
potent
antipsychot
drug
pimozid
figur
screen
reveal
pimozid
select
usp
includ
share
cofactor
compound
found
larg
revers
bind
activ
site
act
via
complex
disrupt
howev
optimis
hit
describ
recent
dub
panel
profil
pimozid
use
diubiquitinmalditof
ms
techniqu
suggest
compound
less
select
previous
thought
inhibit
mani
dub
similar
affin
zhuang
group
maintain
interest
find
addit
inhibitor
recent
publish
extens
structureact
relationship
sar
far
potent
pyrimidinecor
compound
compound
result
optimis
effort
around
weaker
quinazolin
hit
region
found
alter
without
significantli
affect
potenc
orthosubstitu
pendant
phenyl
ring
found
essenti
possibl
replac
trifluoromethyl
group
varieti
substitu
move
either
meta
para
posit
led
complet
loss
activ
radic
chang
core
result
identif
make
structur
chang
part
zhuang
group
show
sar
addit
isopropyl
group
crucial
chang
lipophil
group
polar
ether
alcohol
keton
result
loss
potenc
highli
select
show
effect
dub
unrel
proteas
kinas
cerep
lead
profil
screen
hit
target
howev
despit
compound
nm
ic
ec
cell
surviv
assay
unlik
due
poor
cell
permeabl
sinc
report
permeabl
high
p
app
cm
efflux
ratio
found
howev
sensitis
nonsmal
cell
lung
cancer
cell
cisplatin
team
report
limit
success
improv
metabol
stabil
seri
human
liver
microsom
min
rat
liver
microsom
min
consist
high
clearanc
found
rat
mlminkg
dandrea
group
report
screen
compound
ubrho
assay
use
dtt
reduc
agent
identifi
inhibitor
howev
quinonecontain
compound
found
neglig
select
diubiquitinmalditof
ms
dub
profil
also
show
close
analogu
inhibit
approxim
half
dub
screen
like
redox
cycl
compound
rcc
inhibit
dub
oxid
catalyt
cystein
report
sever
structur
motif
includ
quinon
especi
pronounc
presenc
dtt
attract
mechan
proteas
inhibit
sinc
rcc
promiscu
activ
brik
group
also
uncov
similar
quinonecontain
rcc
screen
case
abl
confirm
oxid
mechan
proteas
inhibit
ms
analysi
preand
posttreat
compound
increas
molecular
weight
da
confirm
oxid
presum
catalyt
cystein
side
chain
thiol
rsh
sulfin
acid
rso
h
patent
public
novarti
describ
small
set
includ
figur
andor
inhibitor
treatment
prolif
diseas
cancer
unfortun
potenc
quot
seri
probabl
druglik
sinc
warhead
known
form
revers
coval
bond
activ
site
cystein
residu
clinic
preced
novarti
cathepsin
k
inhibitor
dutacatib
reach
phase
osteoporosi
trial
design
hausp
inhibitor
subject
public
past
year
dub
addit
astrazeneca
screen
paper
hybrigen
progenra
almac
discoveri
genentech
publish
detail
search
inhibitor
shown
indirectli
regul
tumour
suppressor
deubiquitin
henc
stabilis
polyubiquitin
form
oncoprotein
inhibit
expect
increas
level
lead
antitumour
activ
hybrigen
screen
compound
use
ubamc
assay
identifi
figur
inhibitor
ic
compound
shown
revers
compet
iodoacetamid
thiolalkyl
agent
indic
protect
activ
site
cystein
paper
group
show
potent
nm
paper
also
show
electrondefici
ring
highli
electrophil
sinc
dimethylamin
displac
nitril
group
para
keton
room
temperatur
howev
nitril
displac
unlik
involv
compound
bind
sinc
would
expect
irrevers
step
inconsist
find
initi
hybrigen
paper
nonetheless
reactiv
could
explain
found
diubiquitinmalditof
ms
dub
profil
significantli
inhibit
half
dub
test
dub
except
jamm
also
hybrigen
patent
publish
claim
compound
low
inhibitor
exampl
ic
figur
progenra
thiophen
seri
inhibitor
first
describ
paper
use
activ
probe
assay
show
pandub
inhibitor
contrast
found
inhibit
appreci
cellbas
assay
subsequ
optimis
led
compound
well
potent
significantli
less
reactiv
glutathion
stabl
plasma
factor
import
reduc
clearanc
although
toxicophor
remain
least
nitro
group
found
nonessenti
nitro
cyano
function
group
swap
main
factor
markedli
improv
plasma
stabil
nitro
group
similar
compound
shown
caus
unwant
irrevers
coval
bind
protein
via
nucleophil
aromat
substitut
reaction
despit
weak
level
potenc
utilis
vivo
administ
intraven
iv
inject
mgkg
twice
weekli
week
human
multipl
myeloma
tumourbear
mice
compound
found
inhibit
tumour
growth
prolong
surviv
administ
intraperiton
ip
inject
mgkg
daili
week
orthotop
neuroblastoma
mous
model
show
signific
inhibit
xenograft
growth
interestingli
much
select
hybrigen
compound
diubiquitinmalditof
ms
dub
profil
inhibit
appreci
test
past
year
hybrigen
progenra
describ
sever
addit
seri
inhibitor
figur
weak
compar
thiophen
seri
screen
natur
product
librari
marin
invertebr
extract
research
progenra
found
pyrrol
alkaloid
spongiacidin
c
inhibitor
ic
bind
mechan
propos
exhibit
select
small
panel
test
discov
hybrigen
highthroughput
screen
weak
inhibitor
bind
irrevers
nucleophil
aromat
substitut
onto
electrondefici
heterocycl
consequ
loss
chlorin
mstrypsin
digest
studi
confirm
mechan
interestingli
show
react
almost
entir
activ
site
cystein
prefer
solventexpos
cystein
residu
show
indiscrimin
aryl
agent
consist
select
compound
neglig
activ
recent
hybrigen
patent
seri
piperidin
describ
weak
noncoval
inhibitor
potent
racem
compound
ic
ic
poster
present
research
almac
discoveri
describ
appli
usp
focuss
fragment
screen
campaign
six
usp
discov
optimis
hit
fragment
set
compound
screen
use
surfac
plasmon
reson
spr
detect
techniqu
gave
primari
hit
valid
orthogon
protein
nuclear
magnet
reson
nmr
studi
one
hit
rel
potent
k
spr
ic
biochem
assay
compound
optimis
assist
ligandenzym
complex
xray
structur
much
potent
exampl
nm
although
structur
shown
describ
noncoval
extrem
select
ic
dub
includ
close
relat
dub
progenra
compound
discrimin
clean
redoxaggreg
assay
stabl
human
plasma
glutathion
h
compound
work
wholecel
activ
probe
assay
around
nongenotox
demonstr
stabilis
microsom
hepatocyt
vivo
data
includ
genentech
also
screen
fragment
time
use
nmr
although
littl
detail
known
fragment
found
bind
uniqu
site
palm
portion
distanc
catalyt
triad
could
consist
find
see
later
addit
compound
ic
nm
hybrigen
describ
sever
relat
fuse
triand
tetracycl
seri
inhibitor
treat
wide
rang
diseas
interestingli
oxim
deriv
retain
potenc
inact
ic
oxim
group
respons
select
sinc
parent
keton
low
potenc
figur
anoth
oxim
profil
wide
found
ic
byan
et
al
report
efficaci
administ
compound
ip
inject
mgkg
day
per
week
nonsmal
cell
lung
cancer
mous
xenograft
model
kathman
et
al
describ
synthesis
librari
amidomethyl
methyl
acryl
screen
four
proteas
use
ms
assay
identifi
compound
bind
hit
figur
albeit
extrem
weak
label
interest
sinc
least
michael
acceptor
group
may
act
coval
warhead
clinic
preced
cystein
proteas
rupintrivir
inhibitor
rhinoviru
proteas
progress
phase
ii
trial
agouron
pfizer
addit
gsk
recent
report
phase
data
anoth
structur
relat
compound
coval
irrevers
cathepsin
c
inhibitor
figur
initi
identifi
donato
group
cellbas
janu
kinas
inhibit
screen
seek
improv
inhibitor
antitumour
agent
howev
compound
discov
direct
inhibitor
instead
inhibitor
dub
capabl
modul
ubiquitin
traffick
signal
transduct
group
show
use
activ
probe
cellbas
assay
inhibit
regulatori
particleassoci
cystein
dub
ic
also
inhibit
well
isol
dub
assay
use
ubamc
inhibit
donato
group
use
mgkg
oral
daili
infect
mice
demonstr
antimurin
noroviru
mnv
activ
attribut
compound
activ
sinc
dub
requir
optim
noroviru
infect
anoth
group
show
deplet
etwentysixrel
gene
erg
retard
prostat
tumour
growth
time
inhibitori
activ
administ
ip
inject
mgkg
altern
day
xenograft
mice
propos
mechan
dub
inhibit
recent
propos
donato
group
ms
work
use
show
compound
bind
coval
adduct
lost
proteinligand
complex
dilut
heat
indic
revers
presum
via
retro
michael
addit
reaction
use
uv
absorb
group
demonstr
compound
bound
preferenti
cystein
residu
locat
within
zincfing
structur
element
analys
diubiquitinmalditof
ms
techniqu
found
inhibit
modestli
inhibit
dub
strongli
although
discrep
earlier
claim
partial
select
wider
profil
result
would
tie
fact
approxim
half
dub
cd
predict
zinc
finger
donato
group
describ
slowli
revers
inhibitor
ic
cd
cf
improv
aqueou
solubl
hcl
salt
cf
use
activ
probe
assay
group
also
show
inhibit
dub
close
relat
well
dub
includ
intraperiton
dose
tumourbear
mice
mgkg
daili
week
reveal
compound
significantli
suppress
tumour
growth
dose
mgkg
despit
modest
mous
pharmacokinet
min
shown
sustain
inhibit
vivo
h
author
propos
coval
natur
enabl
dissoci
pharmacokinet
pharmacodynam
term
druglik
michael
acceptor
group
compound
similar
use
principia
biopharma
bruton
tyrosin
kinas
btk
inhibitor
achiev
prolong
ontarget
resid
time
coval
latch
onto
noncatalyt
cystein
compound
repres
exampl
principia
biopharma
recent
announc
complet
phase
clinic
trial
coval
revers
prolong
action
btk
inhibitor
although
exact
ident
unknown
like
relat
compound
liu
et
al
use
ubamc
assay
characteris
figur
inhibitor
ic
valu
activ
anoth
usp
cyld
highthroughput
screen
food
drug
administr
fda
approv
compound
run
identifi
inhibitor
dub
play
key
role
dna
doublestrand
break
repair
potent
hit
type
ii
topoisomeras
inhibitor
mitoxantron
ic
figur
interestingli
although
structur
look
like
potenti
rcc
found
activ
assay
even
reduc
agent
switch
dtt
cystein
regulatori
particl
proteasom
contain
three
dub
metalloproteas
two
cystein
proteas
latter
proteas
mediat
stepwis
ubiquitin
remov
distal
end
polyubiquitin
substrat
two
group
report
inhibitor
enzym
proteostasi
therapeut
target
specif
see
later
linder
group
sought
joint
inhibitor
cystein
proteas
dub
screen
compound
induc
lysosom
apoptosi
pathway
linder
group
discov
figur
proteasom
inhibitor
mechanist
investig
found
inhibit
proteolyt
activ
proteasom
caus
disassoci
activ
probe
assay
either
whole
proteasom
regulatori
particl
show
compound
block
reaction
haemagglutinin
ha
tag
ubiquitin
vinyl
methyl
sulfon
vm
use
purifi
ubamc
assay
shown
ic
later
version
assay
use
ubrho
measur
recoveri
dub
activ
follow
rapid
dilut
complex
inhibitor
shown
revers
indiscrimin
dub
inhibitor
sinc
isol
dub
assay
inhibit
even
though
inhibitori
potenc
modest
linder
group
show
inhibit
tumour
progress
four
differ
vivo
solid
tumour
model
mice
mgkg
subcutan
inject
valid
regulatori
particl
new
anticanc
drug
target
subsequ
mous
vivo
studi
team
show
induc
synergist
antimultipl
myeloma
activ
combin
suberoylanilid
hydroxam
acid
lenalidomid
dexamethason
small
amount
sar
describ
around
use
cell
viabil
assay
found
acrylamid
group
nonessenti
replac
nitro
group
fluorin
almost
effect
cell
viabil
ad
hydroxi
group
phenyl
ring
caus
signific
reduct
effect
figur
howev
could
due
poor
cell
penetr
rather
chang
affin
ringexpand
analogu
twofold
potent
assay
ec
also
improv
aqueou
solubl
make
suitabl
iv
inject
isol
assay
ic
linder
group
explain
loss
potenc
cellular
ec
enrich
compound
cell
support
hypothesi
show
inhibit
wholecel
activ
probe
assay
label
assay
howev
less
consist
profil
kinas
gave
neglig
hit
except
inhibit
wide
dub
profil
dub
gave
one
hit
inhibit
although
reconstitut
ubvm
treat
proteasom
also
panel
show
inhibit
poor
solubl
test
compound
assay
buffer
could
possibl
explan
surpris
result
linder
group
collabor
vivolux
announc
fda
grant
clearanc
proceed
clinic
phase
iii
treatment
relaps
andor
refractori
multipl
myeloma
first
time
compound
progress
clinic
basi
dub
inhibitori
activ
meanwhil
group
proteostasi
therapeut
spent
sever
year
optimis
seri
inhibit
alon
first
lead
compound
initi
harvard
medic
school
seri
licens
proteostasi
therapeut
identifi
highthroughput
screen
compound
reconstitut
ubvmstreat
proteasom
figur
ic
compar
ic
use
proteasom
lack
compound
also
inact
found
cell
permeabl
enhanc
substrat
degrad
cell
block
trim
polyubiquitin
substrat
includ
tau
implic
neurodegen
diseas
close
analogu
figur
affin
even
mm
suggest
keton
might
act
cystein
warhead
potenc
also
found
sensit
natur
posit
phenyl
substitu
exampl
although
fluorin
chlorin
swap
increas
potenc
fourfold
move
chlorin
ortho
posit
result
complet
loss
activ
although
naryl
pyrrol
unattract
structur
motif
associ
promiscu
pharmacolog
shown
replac
rang
attract
heteroaryl
core
pyrazol
continu
activ
area
research
two
addit
patent
publish
recent
first
add
addit
therapeut
use
aryl
keton
inhibitor
antivir
agent
respons
find
up
inhibit
reduc
viral
yield
second
patent
contain
mani
ic
exampl
figur
suggest
proteostasi
therapeut
well
advanc
lead
optimis
stage
support
pipelin
statement
compani
websit
decemb
proteostasi
therapeut
biogen
enter
collabor
research
develop
therapeut
candid
base
inhibit
premis
enhanc
proteasom
activ
therebi
increas
clearanc
brain
aggregationpron
protein
associ
alzheim
parkinson
diseas
juli
proteostasi
therapeut
announc
achiev
key
preclin
mileston
collabor
consequ
receiv
multimillion
dollar
payment
anoth
set
patent
describ
evolut
second
inhibitor
seri
proteostasi
therapeut
reason
activ
fragment
figur
small
chang
amino
substitu
delet
fuse
cyclohexyl
ring
result
larg
loss
potenc
convers
methylenespac
amid
substitut
pyrimidin
ring
found
increas
potenc
part
mission
therapeut
research
develop
druglik
inhibitor
sever
dub
success
cocrystallis
exampl
fuse
thiophen
pyrimidin
seri
cd
xray
structur
result
complex
full
descript
find
along
xray
structur
dubligand
complex
subject
futur
public
howev
figur
show
locat
inhibitor
purpl
dark
grey
print
version
overlaid
publish
structur
blue
dark
grey
print
version
bound
ubiquitin
aldehyd
orang
grey
print
version
pdb
view
orient
use
figur
electron
densiti
inhibitor
overlap
ubiquitin
aldehyd
indic
inhibitori
mechan
block
ubiquitin
pocket
prevent
ubiquitin
substrat
bind
site
bind
finger
palm
region
similar
compound
bind
sarscov
plpro
may
also
similar
genentech
fragment
bind
cd
see
section
gsk
present
brief
detail
search
inhibitor
oncolog
interest
stem
find
report
regul
stabil
adrenerg
receptor
recycl
resensitis
screen
focuss
compound
librari
yield
hit
ic
nm
figur
dub
select
data
present
compound
shown
cell
penetr
effect
modul
level
within
cell
mitochondrialocalis
dub
inhibit
recent
propos
separ
group
approach
treat
parkinson
diseas
cancer
yue
et
al
identifi
inhibitor
screen
compound
cellbas
assay
figur
test
compound
found
induc
elong
mitochondria
mef
cell
without
affect
cell
viabil
howev
concentr
cell
kill
apoptosi
propos
molecular
target
demonstr
biotintag
version
bound
streptavidin
complex
myctag
first
detect
brainspecif
protein
jackson
thompson
probabl
studi
dub
associ
neurodegen
diseas
progress
human
malign
although
mainli
express
neuron
high
level
also
found
nonneuron
tumour
includ
breast
colorect
pancreat
carcinoma
first
inhibitor
describ
liu
et
al
seri
isatin
oxim
identifi
highthroughput
screen
compound
use
ubamc
substrat
compound
found
competit
revers
inhibitor
ic
figur
howev
use
newer
nonamc
assay
mission
therapeut
found
weaker
follow
year
treat
neuron
cultur
prostaglandin
michael
acceptorcontain
found
rais
level
ubiquitin
protein
subsequ
screen
isol
ubamc
show
k
two
micromolar
inhibitor
shown
figur
compound
identifi
inhibitor
k
although
hand
find
approxim
weaker
compound
identifi
silico
screen
apo
xray
structur
subsequ
screen
show
ic
group
respons
xray
structur
apo
complex
solv
structur
bound
irrevers
fluoridedisplac
product
tripeptid
fluoromethyl
keton
fmk
ligand
zvae
ome
fmk
see
figur
weak
inhibitor
requir
concentr
block
reaction
hatag
ubvm
activ
probe
assay
notabl
effect
either
concentr
xray
structur
pdb
show
electrophil
fmk
group
react
activ
site
residu
displac
fluorid
form
thioether
linkag
tripeptid
motif
bind
prime
side
activ
site
away
ubiquitin
bind
site
interest
observ
three
residu
catalyt
triad
unmov
posit
apo
pdb
figur
show
region
shown
figur
overlaid
figur
structur
yellow
light
grey
print
version
blue
dark
grey
print
version
tripeptid
fmk
green
grey
print
version
lack
movement
may
suggest
highli
electrophil
warhead
tripeptid
fmk
capabl
bind
inactiv
form
howev
xray
work
mission
therapeut
sever
inhous
structur
bound
ligand
bear
less
reactiv
druglik
warhead
like
also
reveal
catalyt
triad
inactiv
state
henc
anoth
model
would
consist
structur
exist
partial
activ
state
even
absenc
ubiquitin
bind
activ
state
bind
coval
inhibitor
relax
back
former
inactiv
state
inhibitor
still
attach
silico
screen
group
respons
compound
appli
techniqu
dub
known
involv
program
cell
death
hit
found
figur
weak
ic
contain
toxicophor
structur
similar
earli
hybrigen
hit
ohayon
et
al
describ
use
screen
identifi
quinonecontain
inhibitor
discuss
previous
section
like
rcc
fals
posit
see
section
section
discuss
novarti
inhibitor
seri
trabid
trabid
put
anticanc
target
member
otu
famili
shi
et
al
perform
silico
screen
model
activ
site
trabid
deriv
xray
structur
anoth
otu
unfortun
hit
identifi
dttcontain
assay
probabl
rcc
fals
posit
figur
overlay
xray
structur
apo
yellow
light
grey
print
version
product
react
zvae
ome
fmk
enzym
blue
dark
grey
print
version
ligand
green
grey
print
version
zinc
metalloproteas
dub
associ
regulatori
particl
essenti
substrat
degrad
inhibitor
expect
exert
effect
compar
market
inhibitor
proteolyt
core
see
section
cleav
bioscienc
publish
seri
patent
describ
compound
contain
wellknown
bident
zincbind
motif
exampl
thiolsubstitut
quinolin
figur
analysi
past
decad
research
dub
inhibitor
two
thing
becom
clear
firstli
gener
term
famili
overal
find
effici
druglik
inhibitor
prove
rel
difficult
compar
proteas
famili
secondli
closer
inspect
reveal
dub
creat
equal
definit
amen
smallmolecul
intervent
other
surpris
given
wide
varieti
size
tertiari
structur
relianc
extra
domain
among
divers
famili
lack
warhead
dior
tripeptidederiv
inhibitor
notabl
compar
exampl
numer
exampl
describ
inhibitor
cystein
proteas
member
cathepsin
famili
assumpt
absenc
xray
structur
vast
major
dub
activ
site
dub
commonli
contain
smallmoleculeshap
bind
pocket
sinc
optimis
instead
recognis
narrow
ub
motif
substrat
see
section
support
sever
studi
illustr
cterminu
ubiquitin
without
remaind
ubiquitin
present
littl
dubbind
affin
stein
et
al
show
rang
peptideamc
substrat
base
cterminu
ubiquitin
isot
requir
least
pentapeptid
zargleuargglyglyamc
residu
ubiquitin
appreci
effici
catalysi
k
c
k
valu
drop
substrat
truncat
zglyglyamc
likewis
borodovski
et
al
found
peptidevm
contain
residu
ubiquitin
requir
prevent
varieti
usp
enzym
cell
lysat
react
ubvm
correspond
smaller
vmscap
peptid
unabl
inhibit
usp
enzym
concentr
addit
activ
site
shape
larg
conform
chang
exhibit
dub
upon
ubiquitin
bind
suggest
flexibl
activ
site
may
pose
addit
challeng
optim
fit
inhibitor
associ
fact
dub
activ
site
cystein
may
nucleophil
absenc
ubiquitinmedi
activ
would
expect
pose
problem
activ
site
binder
bear
druglik
warhead
limit
electrophil
howev
state
section
found
case
suggest
binari
activatedinactiv
model
suggest
xray
studi
simplist
explain
good
inhibitori
properti
compound
contain
druglik
warhead
nonetheless
dub
evid
inhibitor
describ
review
highli
reactiv
compound
requir
coval
block
presum
activ
site
cystein
approach
unattract
high
level
reactiv
usual
lead
poor
vivo
exposur
select
includ
probabl
oxid
exampl
alkyl
exampl
aryl
exampl
recognis
analysi
druglik
attract
subject
depend
unmet
need
diseas
question
also
built
assumpt
exampl
despit
contain
electrophil
enon
group
may
compound
steric
hinder
react
coval
protein
would
consist
report
revers
fact
vivo
efficaci
achiev
low
dose
dub
inhibitor
contain
warhead
close
relat
warhead
utilis
nondub
cystein
proteas
inhibitor
clinic
exist
compound
highlight
clinic
preced
howev
weak
convers
cours
research
sever
therapeut
import
dub
discov
coval
activ
site
seri
druglik
unrel
previous
describ
dub
inhibitor
exhibit
good
oral
bioavail
ec
less
nm
cellbas
assay
select
optimis
rang
dub
yield
cocryst
xray
structur
facilit
structurebas
drug
design
public
describ
seri
mission
therapeut
submit
shortli
recent
trend
identifi
druglik
dub
inhibitor
stem
advanc
made
noncoval
seri
certain
usp
inhibitor
proteostasi
therapeut
appear
highqual
lead
especi
sinc
compani
recent
patent
cover
seri
suggest
cyclohexyl
group
may
prove
metabol
vulner
exchang
heterocycl
collabor
biogen
also
indic
confid
develop
natur
seri
xray
structur
exampl
seri
cd
figur
show
bind
smallmolecul
drugshap
caviti
palm
finger
region
given
structur
similar
inhibitor
inhibitor
tempt
specul
equal
druglik
lead
may
bind
similar
region
complex
june
genentech
almac
discoveri
announc
collabor
undisclos
usp
target
wherebi
almac
discoveri
smallmolecul
lead
would
provid
start
point
twoyear
joint
research
programm
almac
discoveri
receiv
upfront
payment
million
elig
million
payment
achiev
predetermin
mileston
given
share
interest
see
section
like
usp
target
sinc
genentech
found
fragment
bind
palm
may
evid
gener
usp
druggabl
site
palmfing
region
cocrystallis
xray
structur
sarscov
plpro
lead
see
figur
add
weight
theori
sinc
structur
viral
dub
similar
usp
famili
sir
philip
cohen
conclud
review
field
predict
futur
notori
difficult
appear
us
although
dub
like
yield
druglik
smallmolecul
inhibit
emerg
trend
area
inhous
work
suggest
signific
proport
good
potenti
